Roth Capital Reiterates “Hold” Rating for Tilray (TLRY)

Tilray (NASDAQ:TLRY)‘s stock had its “hold” rating reaffirmed by research analysts at Roth Capital in a research note issued on Thursday.

Several other research firms have also recently weighed in on TLRY. Zacks Investment Research upgraded shares of Tilray from a “sell” rating to a “hold” rating in a report on Saturday, January 5th. Piper Jaffray Companies started coverage on shares of Tilray in a report on Wednesday, January 9th. They issued an “overweight” rating and a $90.00 price target on the stock. Jefferies Financial Group started coverage on shares of Tilray in a report on Friday, March 8th. They issued an “underperform” rating and a $61.00 price target on the stock. Finally, Seaport Global Securities started coverage on shares of Tilray in a report on Thursday, February 21st. They issued a “neutral” rating and a $81.10 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $106.52.

Shares of Tilray stock traded down $3.09 on Thursday, hitting $67.16. The stock had a trading volume of 1,608,138 shares, compared to its average volume of 1,913,384. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.98 and a current ratio of 5.43. Tilray has a one year low of $20.10 and a one year high of $300.00. The stock has a market capitalization of $6.54 billion and a price-to-earnings ratio of -81.90.

Tilray (NASDAQ:TLRY) last issued its earnings results on Monday, March 18th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.19). Tilray had a negative return on equity of 76.39% and a negative net margin of 157.05%. The firm had revenue of $15.50 million during the quarter, compared to the consensus estimate of $12.85 million. The business’s revenue for the quarter was up 203.9% compared to the same quarter last year. As a group, equities research analysts forecast that Tilray will post -0.86 earnings per share for the current fiscal year.

In other Tilray news, CFO Mark Castaneda sold 30,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $70.43, for a total transaction of $2,112,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CRO Edward Wood Pastorius, Jr. sold 29,422 shares of the firm’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $72.57, for a total value of $2,135,154.54. The disclosure for this sale can be found here. Insiders have sold 229,916 shares of company stock valued at $16,900,414 in the last three months.

A number of institutional investors have recently made changes to their positions in the business. Toronto Dominion Bank purchased a new position in shares of Tilray in the 4th quarter worth about $27,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Tilray in the 4th quarter worth about $71,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Tilray by 7,266.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,105 shares of the company’s stock worth $78,000 after purchasing an additional 1,090 shares during the last quarter. Captrust Financial Advisors purchased a new position in shares of Tilray in the 3rd quarter worth about $103,000. Finally, IFP Advisors Inc raised its position in shares of Tilray by 61.0% in the 4th quarter. IFP Advisors Inc now owns 1,729 shares of the company’s stock worth $130,000 after purchasing an additional 655 shares during the last quarter. 7.91% of the stock is owned by institutional investors and hedge funds.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Further Reading: Stock Symbol

Analyst Recommendations for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.